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Summary
Despite more than two decades of clinical research with che-
motherapy, the outcome of malignant gliomas remains poor.
Recent years have seen major advances in elucidation of the
biology of these tumors, which in turn have led to the current
development of innovative therapeutic strategies. The question
confronting us at the end of the 1990s is whether we should
continue to use and investigate chemotherapy or whether the
time has come for experimental treatments.
As a contribution to this debate, we reviewed the abundant
literature on chemotherapy of malignant glioma, paying spe-
cial attention to methodological features. The new treatment
approaches based on current knowledge about glioma biology
are then briefly summarized.
Assessment of more than 20 years of chemotherapy trials is
discouraging despite a few areas of modest success. Only
patients with specific histology (oligodendroglioma, anaplastic
astrocytoma) and good prognostic factors (young age, good
performance status) may benefit from chemotherapy, with a
possible reversal of neurological dysfunction. However, the
real impact on survival is small (anaplastic astrocytoma) or
undefined (oligodendroglioma). Furthermore, it is unfortu-
nately obvious that the outcome of glioblastoma patients is
not significantly modified by chemotherapy. We believe the time
has come to explore the potential of novel biological therapies
in glioblastoma patients. This could also be proposed for ana-
plastic astrocytoma and oligodendroglioma patients after fail-
ure of chemotherapy.
Key words: brain neoplasms, chemotherapy, gene therapy,
glioma, immunotherapy, review literature
Introduction
Current therapies for malignant gliomas include tumor
removal and irradiation. The neurosurgical procedure is
a mandatory step for the establishment of a precise
diagnosis, and its impact on prognosis is acknowledged
[1, 2], However, the infiltrative behavior of malignant
gliomas precludes their complete resection, and 90% of
glioblastomas recur within 2 cm of the primary site [3].
Postoperative irradiation is therefore commonly admin-
istered, with a significant and reproducible improvement
in survival [4, 5]. Nevertheless, despite surgery and irra-
diation, the prognosis of high-grade glioma patients re-
mains poor, with only a few patients alive two years
after diagnosis [6].
A huge number of clinical studies were performed in
recent decades to determine whether chemotherapy could
influence the outcome of malignant glioma patients. Dis-
appointing results of chemotherapy have raised the sug-
gestion that chemotherapy should perhaps be abandoned.
This is a provocative working hypothesis that may be
valid in certain circumstances, but is probably inad-
equate in others. A critical appraisal of the potential of
chemotherapy in malignant glioma treatment is compli-
cated by numerous methodological problems encoun-
tered in neurooncology and discussed during this review.
The most obvious obstacles to effective chemother-
apy for glioma remain, however, the intrinsic chemo-
resistance of these tumors [7], as well as their location
within the central nervous system (CNS), limiting access
of the drugs to their targets. A first theoretical difficulty
which must be circumvented is the blood brain barrier
(BBB) [8]. Diffusion of drugs through the BBB is de-
pendent upon the size of the molecules (low molecular
weight), liposolubility (high) and fixation rate to plas-
matic proteins (low). However, the role of BBB in limit-
ing drug penetration was probably overestimated. Con-
trast enhancement in neuro-imaging clearly shows that
the BBB permeability is modified in brain tumors: neo-
vessels often display loose tight junctions and defects
in the capillary wall. But alterations of the BBB are
generally less important at the border of the tumor,
which also means in its most actively-growing zone. A
second major obstacle once the drug has passed the
BBB is its diffusion through a network of interstitial
channels in the brain tissue. On their tortuous way to
the target tumor, molecules can still be eliminated or
deactivated by enzyme metabolization, non-specific
binding to proteins, internalization to non-tumoral cells
or reentry in the systemic circulation by recrossing the
BBB [9].
Chemotherapy thus has to face a very potent adver-
sary in an unfavorable microenvironment. In the first
part of this paper, hopes for and limits of chemotherapy
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will be critically reviewed. We will then discuss how the
dramatic advances achieved in the understanding of
glioma biology could open new avenues for the treat-
ment of these tumors.
Monochemotherapy
Nitrosoureas are the leading drugs in glioma chemother-
apy. Response rates to BCNU/CCNU as single agents
can be estimated to vary from 10% to 40% [10-13], and
even reach 64% in a subgroup of patients with anaplastic
astrocytomas [2]. These results must be viewed with great
caution. They are approximate, if not speculative, as they
are from trials carried out in the 1970s before the CTera.
A response rate in the absence of any radiologic evalua-
tion is of questionable validity and certainly includes
patients with stable disease. In these trials, the median
time to tumor progression (MTTP) was 19 to 23 weeks
[10-13].
As for nitrosoureas, vincristine was studied as a single
agent 30 years ago and the authors observed several
instances of clinical improvement [14]. In the absence of
radiological evaluation, it is difficult to extrapolate the
real efficacy of vincristine from these data, even if re-
sponse rates of 20%-50% are generally reported in the
literature [15, 16]. However, on the basis of these obser-
vations, vincristine was introduced in polychemother-
apy regimens currently used for glioma.
Response rates reached 6%-26% in trials investigat-
ing procarbazine, with a MTTP of seven to 12 months in
pretreated patients [17, 18]. More recently, procarbazine
was reconsidered with interest because of its depleting
activity towards methylguanine-DNA methyltransferase
(MGMT) [19], an enzyme involved in malignant glioma
resistance to nitrosoureas [7]. In a pilot study with 21
patients, procarbazine 200 mg/m2 was delivered on days
1-5 to deplete MGMT before administration of BCNU
80 mg/m2 on days 3-5. The response rate was 41%, and
the MTTP and median survival 30 weeks [19]. However,
these interesting results were accompanied by severe
toxicity, and there was no evident correlation between
MGMT depletion measured in monocytes and clinical
responses. These preliminary data require confirmation.
Several other drugs have been evaluated as single
agents, including platin compounds, epidophyllotoxins,
thiotepa, piritrexim, 13-cis retinoid acid, all with very
limited success [15, 16]. The use of paclitaxel in brain
tumors is theoretically attractive because of its high
lipophility but tempered by a high molecular weight
and binding level to plasmatic proteins. Paclitaxel con-
centration was measured in the plasma, cerebro-spinal
fluid, brain and tumor tissue of three previously irradi-
ated patients after intravenous infusion (175 mg/m2):
tumor tissue drug concentrations were in the therapeu-
tic range in all three patients [20], whereas the concen-
tration was low in normal brain tissue. This suggested
that paclitaxel could not cross the intact BBB. Paclitaxel
was investigated on the basis of these experimental data.
but only 10% to 20% of pretreated patients achieved a
partial response (PR) [21, 22].
There has recently been considerable interest in temo-
zolomide, an imidotetrazine analog of dacarbazine
(DTIC). Unlike DTIC, temozolomide does not require
hepatic activation and displays an excellent oral bioa-
vailability. Based on encouraging responses observed
during a phase I study [23], temozolomide was adminis-
tered to 48 patients with recurrent glioma after radio-
therapy. Strict criteria of response were not applied.
Objective clinical and radiologic responses were reported
in 25% of the patients [24]. Because of these results, the
low toxicity of the drug and the convenience of its use
by mostly unfit patients, temozolomide was further de-
veloped. Two multicentric phase II studies including
glioblastomas and anaplastic astrocytomas, respectively,
have recently been completed. The design of these trials
was excellent, with rigorous response criteria, central-
ized pathological and radiological reviews as well as
monthly quality-of-life assessment. Preliminary data re-
garding the first 100 patients included are available for
anaplastic astrocytomas only. The response rate is 42%
with strict response criteria, but 41% of included pa-
tients were non-evaluable, mainly (29%) because of in-
correct histological diagnoses [25]. This very high rate of
non-evaluable patients in a well-designed study with
pathological review raises doubts about the validity of
data coming from most other studies which lack a cen-
tralized diagnosis review. Another item of information
which is expected to emerge from these two studies
including a large number of patients is the impact of
temozolomide therapy on the quality of life in glioblas-
toma and anaplastic astrocytoma patients.
Polychemotherapy
The most commonly used multiagent regimen is PCV.
Originally described in 1975, PCV was revised in 1978
and 1980, and comprises in its final form CCNU 110
mg/m2 Dl, procarbazine 60 mg/m2 D8-21 and vincris-
tine 1.4 mg/m2 D8 + 29 [26]. Forty-six patients were
treated by this final regimen, which for 40% of them was
the first-line chemotherapy. The response rate for all
patients was 26%, reached 42% in the subgroup of
unpretreated patients and was only 17% in the subgroup
of glioblastoma patients (pretreated or not). The overall
MTTP was 26 weeks. In this study strict response crite-
ria were not applied, and subsequent improvement of at
least two of three parameters (neurologic examination,
radionuclide and CT Scan) was considered as a re-
sponse. Moreover, five "low-grade astrocytomas' were
included and their outcome was not detailed. However,
these results formed the rationale for the further use of
PCV in either relapsing or newly diagnosed patients.
Procarbazine and vincristine were also associated
with mechlorethamine in a MOP combination. Interest
in this regimen in brain tumors was triggered by the
pediatric experience [27, 28]. Thirty-one adult patients
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with recurrent malignant glioma entered a phase II study
with separate results for measurable and evaluable dis-
eases. The response rate (complete remission + PR) was
58% in measurable tumors, 50% in evaluable tumors,
37% in glioblastomas (/? = 16) and 100% in anaplastic
astrocytomas (/? = 6). The median survival was 30 weeks
for all assessable patients and 60 weeks for responders
[29]. Interestingly, cyclophosphamide and the vincristine
combination without procarbazine seems to have some
activity as well [30]. Taken together, these data suggest
that alkylating agents exert a potent antiglioma effect
despite their limited diffusion through the BBB, and that
a combination of procarbazine, vincristine and an alky-
lating agent deserves a larger-scale study.
More recently, interesting results were obtained with
the ICE regimen (ifosfamide, carboplatin and etoposide)
in a series of 36 well-defined patients who were all pre-
treated with surgery, irradiation and nitrosoureas [31].
Five complete responses (CR) and five PR were re-
ported, with an overall response rate of 28% (95% CI:
14%—45%). Strict response criteria were used, and glio-
blastoma appeared to be as sensitive as anaplastic glio-
ma to this regimen. MTTP (13 weeks) and median
survival (29 weeks) for all patients remained low, but
responders seemed to benefit from this effective regimen
(MTTP 22 weeks, median survival 44 weeks). As clearly
described by the authors, this was achieved at the price
of a severe hematological toxicity.
A complex association of six drugs (thioguanine,
procarbazine, dibromodulcitol, CCNU, 5-FU, hydroxy-
urea) was tested with the objective of overcoming a
presumed resistance to nitrosoureas, with most of the
drugs being administered at an infratherapeutic level
[32]. Seventy-five evaluable patients with malignant glio-
ma were included in this study. The response rate of 32%
must be viewed with some caution, as the criteria were
based on a subjective scale in the CT/MRI evaluation by
the neuroradiologist.
A common feature observed in the majority of studies
(mono- or poly-chemotherapy) is that chemotherapy is
more likely to benefit young patients with a good perfor-
mance status and an anaplastic astrocytoma subtype.
This was confirmed in a retrospective study specially
designed to address this question [33] and in adjuvant
chemotherapy studies [5, 13].
Adjuvant chemotherapy
In the literature, 'adjuvant' chemotherapy in malignant
gliomas is generally understood as chemotherapy fol-
lowing initial surgical excision of the tumor and sub-
sequent irradiation. Unlike adjuvant treatment in other
oncological fields, it does not imply the absence of
residual disease at the time of treatment nor a tendency
to its systemic control, but points to a better local control.
Reading about response rates and not only survival in
adjuvant studies is highly unusual for the medical oncol-
ogist. We believe that the term 'adjuvant therapies'
should be restricted to the cases in which a macroscopi-
cally total or at least subtotal excision has been possible.
Chemotherapy in unresectable malignant gliomas or
after surgical biopsy alone should be refered to as first-
line chemotherapy.
The first randomized study testing adjuvant chemo-
therapy was performed betw...i 1972 and 1975 by the
Brain Tumor Cooperative Group [5]. Patients treated
with BCNU + radiotherapy had a median survival of 51
weeks compared to 36 weeks for patients treated with
radiotherapy alone. Despite a trend in favor of adjuvant
BCNU, this difference was not statistically significant.
Whether or not there was a difference in the outcomes of
anaplastic astrocytoma and glioblastoma patients was
unfortunately not addressed.
A further randomized comparison between postoper-
ative radiotherapy alone or an adjuvant treatment of
BCNU, dibromodulcitol and radiotherapy was con-
ducted by the EORTC: chemotherapy induced a slight
but significant improvement of median survival (13 ver-
sus 10.4 months) and MTTP (8.1 versus 6.7 months) in
255 eligible patients. This benefit was more pronounced
for anaplastic astrocytoma than for glioblastoma but
without reaching a significant level in any subgroup [34].
The real effect of dibromodulcitol in these results is
questionable in view of the limited role of this drug in
glioma treatment. Despite their statistical significance
the previously cited results clearly indicate that the
survival benefit is very limited, with minimal impact for
the individual.
PCV was also tested as an adjuvant treatment and
compared to BCNU. PCV induced a significant amelio-
ration in MTTP (126 versus 63 weeks) and median sur-
vival (157 versus 82 weeks) compared to BCNU for
anaplastic astrocytoma patients [35]. These patients had
good prognostic factors, with a mean age of less than
46 years. In contrast, no difference appeared among
glioblastoma patients.
All of the published studies on this topic included only
a limited number of patients. A meta-analysis of 16
randomized trials was therefore performed in 1993 [13].
All of the 16 compared radiotherapy alone versus radio-
therapy plus chemotherapy and were published between
1975 and 1989. The increase in survival with radiotherapy
and chemotherapy was 10.1% at one year (95% CI: 6.8%-
13.3%) and 8.6% at two years (95% CI: 5.2%-12.0%).
The maximal survival advantage with chemotherapy
was seen later (18-24 months) for glioblastoma patients
than for anaplastic astrocytoma patients (12-18 months).
This suggests that mainly long-survivor glioblastoma
patients might benefit by adjuvant chemotherapy, which
probably means patients with initial favorable prognos-
tic factors (young age, minimal residual tumor, good
performance status). Trials included in this meta-analy-
sis were very heterogeneous, especially regarding histo-
logic and age characteristics, statistical power was often
insufficient and 'intent-to-treat' analysis was seldom used
[36].
Finally, it is noteworthy that there has been no
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randomized study comparing adjuvant chemotherapy
with the same regimen at first relapse.
The special case of anaplastic oligodendrogliomas
Oligodendrogliomas are rare neoplasms arising from the
oligodendrocytes and representing only 5%-10% of
gliomas. They are generally slowly-progressing tumors,
with a better prognosis than those of anaplastic astrocy-
tomas and glioblastomas [37] but which may sometimes
become more aggressive with 'contrast-enhancement'
and acquire anaplastic characteristics. In addition to
their histological and biological specificities [38], ag-
gressive oligodendrogliomas (progressive symptoms or
anaplastic subtype) were shown to be highly sensitive to
chemotherapy. Thirty-three patients were treated after
initial diagnosis or with recurrent disease in a multicen-
tric phase II study [39]; most of them were preirradiated
but all were chemotherapy-naive. Of 24 evaluable pa-
tients, nine (38%) achieved a CR with an overall response
rate (CR + PR) of 75%. Patients with preexisting low-
grade oligodendroglioma had a response rate of 90%
and patients with necrotic tumors 67%. It is noteworthy
that four CR and three PR were achieved among nine
patients treated by chemotherapy before irradiation. The
MTTP was 25.2 months for patients with CR and 14.2
months for patients with PR. There was no significant
difference in response rate between irradiated and non-
irradiated patients. Even though the patients included
had good prognostic factors, this trial, performed accord-
ing to rigorous methodologic criteria, demonstrated the
chemosensitivity of anaplastic oligodendrogliomas.
Despite this unusual efficacy, several questions remain
unanswered; for instance, it is still not known whether
PCV administered as an adjuvant therapy prolongs tu-
mor control and/or survival. This question is currently
being addressed in an RTOG randomized study com-
paring radiotherapy alone with PCV followed by radio-
therapy. In addition, the questions of whether PCV must
be given initially or later at the time of relapse, and
whether PCV has the potential to delay radiotherapy
remain unanswered. High-dose thiotepa with stem-cell
rescue is also currently under investigation with the
objective of deferring radiotherapy and its secondary
neurological effects [40]. This regimen can also be con-
sidered a promising salvage treatment.
Whether the oligodendroglial component of mixed
anaplastic oligoastrocytoma do confer to these tumors
a sensitivity similar to that of oligodendroglioma is
unknown. The major problem is the lack of well-defined
histological criteria. However, some reports suggest that
these tumors can respond to PCV as well [41].
Polymers and interstitial chemotherapy
As stated in the introduction 90% of malignant glioma
relapses occur within 2 cm of the original resection site
[3]; an improvement in local control might prevent or
delay recurrence and have an impact on clinical symp-
toms or survival. Administration of chemotherapy in the
tumor bed or in the tumor itself bestows the potential
advantages of bypassing the BBB, reducing chemother-
apy-induced systemic toxicity, increasing drug concen-
tration at the target site and lengthening the duration of
tumor exposure to the drug. Three main techniques for
delivering drugs in the tumor or in the tumor bed have
been employed: Ommaya reservoir, implantable pumps
or surgically implantable polymer matrices loaded with
the drugs.
Polymer matrices have theoretical advantages over
the other possibilities. They are not subject to blockage
by clogging or necrotic material and they do not require
subcutaneous injections with their inherent infectious
risk. They are not dependent on patient compliance and
do not need maintenance. But they are not refillable and
surgery is necessary for implantation [42].
In a phase I-II study assessing BCNU disks there was
neither local nor systemic toxicity [43]. A multicentric
randomized trial with 222 patients compared implanta-
tion of BCNU-wafers versus placebo-containing wafers.
Indication for open surgical reintervention was deter-
mined by an independent surgeon not involved in the
study. No unexpected toxicity was observed. Median
survival was longer (31 versus 23 weeks) with drug-
containing polymers. In patients with glioblastoma six-
month survival was 50% greater in those treated with
BCNU discs than in the placebo group but published
survival curves are disappointingly superimposable
afterwards [44]. Even if current benefits are limited,
with minimal impact for the individual, polymer delivery
systems provide novel ways to reach malignant gliomas
with various agents. The minimal toxicity of this tech-
nique opens the door to the local administration of
drugs that do not pass the BBB, or cytokines or genetic
material that might be tested in an adjuvant setting.
However, the probability that such approaches will al-
low deep penetration into cerebral tissues should not be
over-estimated, since the penetration of antineoplastic
drugs remains generally under 2 mm except for dextran,
a high-molecular-weight water-soluble molecule [9].
Intra-arterial chemotherapy and high-dose
chemotherapy
Augmentation of the dose of chemotherapy delivered to
glioma has been intensively attempted in the past decade
using intra-arterial (i.a.) chemotherapy or intensive che-
motherapy followed by bone marrow autograft or pe-
ripheric stem cell rescue. Most studies focused on nitro-
soureas. Results for relapsing glioma or in the adjuvant
setting are disappointing, with severe toxicities and high
rates of therapy-related death [45-53]. A detailed de-
scription of this complex field is beyond the scope of this
review. We believe, as the majority of the authors of the
above-cited publications, that i.a. and high-dose chemo-
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therapies do not improve the outcome of malignant
gliomas and that these unacceptably toxic approaches
should be avoided. Oligodendroglioma may be the ex-
ception, as discussed above [40].
Future studies on chemotherapy: A higher
methodological standard is needed
The methodological difficulties pointed out in the field
of malignant gliomas in the course of this review remain
a major problem that contributes to the 'opacity' sur-
rounding brain tumors in the field of medical oncology.
Even if some specificities of malignant gliomas partly
'explain' these pitfalls, more rigorous rules must be ap-
plied in the conduct of future studies.
A first crucial prerequisite is a precise diagnosis. As
discussed, glioblastoma, anaplastic astrocytoma and
oligodendroglioma are tumors with widely differing be-
haviors and responses to chemotherapy. Phase II studies
should focus on single tumor types and patients in phase
III studies should be stratified according to the histology
of their respective tumors, just as they should be forage,
performance status and previous treatment. Whenever
there is any doubt about diagnosis (change of tumor
grade, radiation-induced necrosis), a new biopsy must
be the rule. Furthermore, a central pathology review
should be mandatory in any multicentric study.
Response criteria are to be strictly defined and end-
points should not be limited to symptomatic criteria or
MTTP only [54, 55]. We believe that the interest in a new
drug that helps to reduce symptoms should not be mis-
taken for scientific proof of an antitumoral effect. Both
items of information are of interest for the clinical
oncologist but evidence of tumor reduction remains the
cornerstone of oncological evaluation. The classical def-
inition of CR and PR (^50% reduction in the product of
the two largest perpendicular cross-sectional diameters
of the tumor) was adopted to select in phase II studies
the drugs with the best chances of yielding meaningful
disease control or survival benefit and of preventing
patients from being included in pointless larger phase
III studies. Common adherence to these rules also re-
mains necessary for a valid comparison of results, as
outlined in the detailed recommendations of Macdonald
[56]. Therefore, calling stable patients responders ap-
pears confusing. Unless expressly specified in the text,
response rates in the present review adhere to the com-
monly accepted oncologic criteria.
Since objective measures of gliomas may be quite
difficult, especially for infiltrative or multifocal tumors,
MTTP can provide appropriate complementary infor-
mation [54, 55]. In our opinion, lesions not amenable to
the placement of perpendicular cross-sectional diame-
ters because of their geometry should not be excluded
from clinical studies for purely methodological reasons.
Indeed, it seems appropriate to define objective qualita-
tive response on CTor MRI for these evaluable but non-
measurable tumors. The 'MOP study' [29] is a good
example of this practice with two subgroups of patients
(measurable vs. evaluable disease) analyzed and pre-
sented separately. Exclusion of evaluable non-measura-
ble gliomas might constitute a significant bias as these
tumors might have a worse prognosis than easily meas-
urable lesions.
Furthermore, a central imaging review by one or
several independent neuroradiologists is mandatory in
multicentric studies. An additional confounding factor
is the common use of cortisone. Any clinical or radio-
logical stabilisation or improvement can be considered
only under unchanged or reduced doses of steroids.
Finally, we would like to emphasize the absolute
necessity of including quality-of-life and cost-effective-
ness analyses in current clinical studies. As survival
benefit induced by chemotherapy is minimal to date, we
feel more and more strongly the absence of reliable
information in these two fields. It is, of course, difficult
and dangerous to evaluate the 'price' of a few weeks of
life, but it does not appear to justify worsening of the
patient's quality of life at high cost for society. Should
therapeutic advances appear in the future, accurate data
would be essential in any attempt to persuade the
medical community and public health authorities to
modify the current negative approach to malignant glio-
ma treatment.
Experimental treatments
The genesis and progression of a tumor result from a
series of complex biological mechanisms, including loss
of cell cycle control, neo-angiogenesis and evasion of
immune control. The remarkable advances achieved in
these research fields open new avenues for treatment of
malignant glioma patients by targeting cell prolifera-
tion, cell death, neo-angiogenesis or restoring an appro-
priate immune response. A detailed description of these
fascinating topics is not the present objective, but these
new therapeutical concepts are briefly summarized to
explain why they should be integrated in the current
management of glioma patients.
Oncogene inactivation and tumor suppressor gene
replacement
As for most cancers, multiple genetic events contribute
to the malignant transformation of astrocytes (Figure 1).
Oncogenes have dominant effects and code for proteins
stimulating cell growth or inhibiting apopotosis. Mostly
by gene amplification, several members of the protein-
tyrosine kinase receptor family are overexpressed in
malignant glioma, including the epidermal growth fac-
tor receptor (EGFR), the platelet-derived growth factor
receptor-a (PDGFRa) and the c-met genes [38]. Inter-
estingly, the EGFR is also frequently mutated, leading
to the constitutive activation of its tyrosine kinase activ-
ity and, consequently, to enhanced cell proliferation and
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Figure I. Simplified schema of oncogenes and tumor suppressor genes
involved in the process of malignant transformation of astrocytes.
Abbreviations: LOH - loss of heterozygoty; EGFR - epidermal
growth factor-receptor; PDGFRa - platelet-derived growth factor
receptor-a; Rb - retinoblastoma protein, mdm2 - minute double
minute; CDK-4 - cyclin dependent kinase-4.
tumorigenicity of glioma cell lines in nude mice [57, 58].
Numerous strategies are currently being investigated to
specifically inhibit EGFR, using antibodies, immuno-
conjugates or antisense technology.
Several tumor suppressor genes have been shown to
be altered in glioma. This was initially suspected be-
cause of the numerous genetic losses detected by caryo-
type and loss of heterozygoty (LOH) studies. LOH has
been described in chromosomes lp, 9p, lOp, lOq, lip,
13q, 17p, 19q, and 22q. In some cases, the tumor sup-
pressor genes present in the deleted chromosomic re-
gions have been identified. For instance, the region de-
leted in chromosome 17p includes the/753 gene [59]. P53
plays crucial roles in cell homeostasis and can prevent
malignant transformation, by inducing apoptosis or by
blocking cells in Gl phase (Figure 2) to permit DNA
reparation. Additional mechanisms lead to non-func-
tional p53 in glioma, including various types of mutation
and the amplification of the mdm2 gene, whose product
binds to p53 and catalyses its proteolytic degradation
[60]. Alterations ofp53 seem to be an early event in the
genetic progression of glioma since they are observed in
all grades of glioma.
Other suppressor genes, encoding p!6 and pl5, are
frequently deleted or not expressed in malignant glioma
[61, 62]. By inhibiting cylin-dependent kinases (CDK),
Activation
of transcription
' p1S,p16,
pS3 -— p21
Figure 2. Simplified and schematic view of the main proteins involved
in the control of cell cycle. The balance between cell proliferation
(S phase) and cell quiescence (Gl phase) is tightly regulated. During
the S phase, cyclin Dl proteins associate with cyclin-dependent kinases
(CDK) to phosphorylate (P) the Rb protein, leading to the liberation
of the E2F-l and DP-I transcription factors and the subsequent syn-
thesis of several molecules involved in cell proliferation. This prolifer-
ative activity is counter-balanced by CDK inhibitory factors (pl5, pl6,
p21). The expression otp2l is regulated by/755. The binding complex
between cyclin Dl, CDK and CDK inhibitory factors prevents the
phosphorylation of the Rb protein. Rb is therefore able to retain E2F-l
and DP-l transcription factors and thus to prevent their effects (cells
remain in Gl phase). The mechanisms identified that push the glioma
cell into the S phase are described in the text.
they also play a key role in the control of the cell cycle
(Figure 2). Several mechanisms that can help propel the
glioma cell into the S-phase have been identified: (i)
absence of CDK inhibitors (pJ5, pl6, p21); (ii) amplifi-
cation of CDK-4 [63]; (iii) deletion or mutation of the
Rb gene itself [64] which ensures that the E2F-l and
DP-l transcription factors continuously exert their pro-
liferative effects. Interestingly, both of the latter events
take place when the pl6 gene is intact and correctly
expressed [65]. Finally, intense efforts are currently
underway to identify the tumor suppressor genes as-
sumed to be present in the chromosome 10 deletion, a
genetic hallmark of glioblastoma. A first tumor sup-
pressor gene candidate, called PTEN (Phosphatase and
Tensin homolog deleted on chromosome Ten) was re-
cently characterized [66].
Both alleles of a tumor suppressor gene usually have
to be inactivated to alter the anti-proliferative functions
of their products. It thus appears attractive to restore
normal growth control by transfecting one functional
copy of a given tumor suppressor gene. To date, major
attempts have been made with thep53 gene. Restoring a
p53 function should theoretically lead to growth arrest
or induce apoptosis, and this was actually observed in
vitro [67, 68]. Since the presence of functional p53 has
been shown to modulate chemoresistance [69], another
possible advantage of the gene transfer of wild type (wt)
p53 may be sensitisation to chemotherapy. This was
recently suggested in animal models where the intra-
tumoral administration of an adenovirus containing wt
p53 drastically augmented the pro-apopototic properties
of cisplatin [70]. Thus, combining biological therapies
with current treatments appears to provide some ration-
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ale for future studies. Several gene therapy clinical trials
designed to restore the p53 function are ongoing in differ-
ent cancers [71], but to our knowledge not in malignant
glioma. Some local responses have recently been reported
following the administration of a retroviral-wt/?55 gene
construct in lung cancer lesions [72]. Intense efforts are
ongoing in an attempt to resolve some critical difficul-
ties, such as the potential toxicities on normal cells, the
low ratio of in vivo tumor cell-targeting with the current
procedures, and immune responses against the vector
limiting the efficacy of repetitive administrations.
Neo-angiogenesis inhibition
It is now acknowledged that tumors may remain in a
state of dormancy until they establish a blood supply for
receiving oxygen and nutrients. This process of neo-
angiogenesis implies successive ordered events in which
a large number of players participate. Endothelial cells
migrate, proliferate, should re-organize into a three-
dimensional vascular structure and maintain the vessel
continuity. Numerous factors with angiogenic properties
have been identified, and their effects are counter-
balanced by potent endogeneous inhibitors of angio-
genesis (Table 1). Vascular endothelial growth factor
(VEGF) was shown to play a key role in angiogenesis of
glioma, recapitulating embryogenetic processes. VEGF
binds to two specific tyrosine kinase receptors, called
flk-1 and flt-1. VEGF and its receptors are down-regu-
lated in the normal adult brain. In contrast, glioblasto-
ma cells produce high levels of VEGF, whilst both flt-1
and flk-1 are expressed by proliferating endothelial cells
of glioma, leading to the establishment of a paracrine
loop. Interestingly, the expression of VEGF is strongly
enhanced around areas of necrosis, in pseudopalisading
tumor cells (Figure 3). This suggests that hypoxia can
be a major inducer of VEGF expression, and hypoxia-
sensing regions are actually present in the untranslated
regions of the VEGF gene [73].
Several approaches have been developed to inhibit the
effects mediated by VEGF, including antisense technol-
ogy and monoclonal antibodies [74]. Perhaps the most
Table I. The process of angiogenesis is regulated by factors with a)
pro- and b) anti-angiogenic effects (non exhaustive list).
a) Angiogenic factors b) Anti-angiogenic factors
Vascular endothelial growth factor Thrombospondin-1
(VEGF)
Platelet derived growth factor 2 Platelet Factor 4
(PDGFa)
Basic fibroblast growth factor (bFGF) Angiostatin
Transforming growth factor a (TGFa) Interferon-a
Transforming growth factor (5 (TGFP) Tissue inhibitors of metallo-
Epidermal growth factor (EGF)
Fibroblast growth factors
Interleukin-8
Hepatocyte growth factor
proteinases
Endostatin
Figure 3. Expression of VEGF is more intense in regions surrounding
necrosis. VEGF mRNA expression (in situ hybridization) is predom-
inantly seen on palisading cells in a glioblastoma [a) dark-field and b)
corresponding light-field micrographs] (courtesy I. Desbaillets and
E. G.VanMeir).
impressive results were obtained by disrupting the VEGF-
receptors signal transduction [75, 76]. The authors as-
sumed that blocking the VEGF-receptor activities could
inhibit the proliferation of endothelial cells and decrease
the tumor growth. They tested their hypothesis using C6
rat glioma cells implanted either subcutaneously in nude
mice [75] or intracerebrally [76]. Cells producing retro-
virus encoding a dominant-negative mutant of the Flk-1
receptor were co-injected or administered five days after
implantation of the C6 tumor cells. This recombinant
retrovirus can infect endothelial cells in vivo, and a major
inhibition of angiogenesis was observed, with delaying
of tumor growth and prolonged survival in treated ani-
mals. More recently, the potential of anti-angiogenic
factors was also pointed out, since an adenoviral vector
expressing a modified platelet factor 4 (PF4) (see Table 1)
was reported to inhibit the growth of glioma implanted
intracerebrally [77]. These selected examples show that
the anti-angiogenesis approach should now be investi-
gated in the setting of human glioma.
Specific immunotherapy
It is now well recognized that immune cells, in a com-
plex network of intercellular interactions and cytokine-
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Figure 4 Schematic view of the antigen-specific interactions between
tumor cells and T lymphocytes. Tumor antigens are processed by
cancer cells and presented by major histocompatibility antigens (MHC)
class I molecules to CD8+ T cells and in some circumstances by MHC
class II molecules to CD4+ T cells. Tumor cells are probably helped in
this function by specialized cells (APC - antigen presenting cells; eg.,
dendritic cells, Langerhans cells). APC can capture some tumor anti-
gens, process and present them mainly (but not exclusively) in a MHC
class II restricted way. In addition to this antigen-specific interaction
between M HC-peptide complexes and the T cell receptor (TCR), T cell
clonal activation requires a second signal provided by costimulatory
molecules. The absence of a second signal results in the specific unre-
sponsiveness of T cells, or anergy. Interactions between B7 and CD28
molecules play a pivotal role in determining immune reactivity versus
anergy [78]. However, recent results suggest that costimulation path-
ways are more complex than initially thought. It appears that CD28
mediates stimulatory effects, whereas CTLA-4, a molecule with high
homology to CD28, may be a negative regulator of T cell responses [79].
mediated signals, can in some circumstances help pro-
tect the host against cancer. There is also cumulative
evidence that T lymphocytes play a critical role in the
anti-tumor response. The initiation or priming of a spe-
cific T cell response requires an antigen-specific interac-
tion between tumor cells and T lymphocytes, probably
with the help of professional antigen presenting cells
(APC) (Figure 4).
In the case of glioma, several aspects of the dialogue
between tumor cells and T cells remain poorly charac-
terized (see ref. [80] for a more detailed discussion of
this topics). Moreover, several mechanisms concur to
create a state of immunosuppression in the glioma
microenvironment, including the secretion of various
cytokines such as TGF-J32 or interleukin-10 [81, 82], or
cell-cell interactions with Fas ligand expression by glio-
ma cells as a first candidate [83, 84]. Consequently, the
growth of aggressive tumors such as malignant glioma
may be due to an imbalance in tumor-host relationships
that could result from many possible alterations in the
different components of the immune response (Table 2).
It has been proposed that immunizations using either
tumor antigens themselves (but to date no glioma anti-
gen able to elicit an immune response has been charac-
terized in vivo) or genetically modified tumor cells as
Table 2. Possible mechanisms of immune-escape by glioma (most are
hypothetical).
Tumor antigens are not presented to immune cells
Lack of tumor antigen
Lack of MHC class I or II molecules
Lack of TAP (transporter associated with antigen processing)
molecules
Lack of professional APC in the local environment of glioma
Tumor antigens are presented, but do not elicit an immune response
Tumor peptide density below the threshold level required forT-cell
activation
Onco-fetal antigen for which immune tolerance has been established
Costimulatory signal absent or with inhibitory effect
Appearance of new epitopes that are tolerogenic rather than
immunogenic
Inefficacy of immune response
Limited accessibility of immune cells to the CNS
Inappropriate immune stimulation (e.g.. solely T helper and
antibody response)
Immunosuppressive microenvironment
Soluble factors (TGF-P2, IL-10, PGE2, IL-1R antagonist)
Cell-cell contact (FasL)
immunogens could tilt the balance in favor of an effi-
cient antitumoral response. It has been shown in in vivo
models that such immunogens could induce not only a
local immune response at the site of injection, but also
systemic effects [85]. In the particular case of glioma,
these vaccination approaches must take into account the
accessibility of effector cells to their targets in the CNS.
It is now clear that there is a significant trafficking of
activated T cells through the CNS [86, 87] and that
T cells primed by glioma cells in the periphery can
recirculate and reach the brain to mediate their anti-
tumor effects [88-91].
Several approaches using genetically modified tumor
cells as vaccines have been investigated in animal models
in an attempt to enhance the immunogenicity of glioma.
The most interesting results reported to date were ob-
tained by enhancement of lymphocyte responsiveness
with tumor cells transfected with the interleukin-7 gene
[88], and by inhibition of the local immunosuppression
using TGF-p2 antisense constructs [92]. The enhance-
ment of antigen presentation and T cell costimulation is
another promising approach and results achieved with
GM-CSF, B7, or CIITA (a transcription factor playing a
critical role in the regulation of MHC class II molecules)
genes should be available in the near future. In addition,
promising results have recently been reported in a model
of melanoma (B16 murine melanoma) located in the
CNS. Efficient antitumor response was obtained using
GM-CSF gene modified melanoma cells [93] or bone
marrow-generated dendritic cells pulsed with tumor ex-
tracts or tumor RNA [94].
The strict localization of glioma in the CNS, with
only occasional metastases, may appear to be an ad-
vantage for approaches employing intratumoral delivery.
Genetically modified cells can be implanted directly in
the tumor (or the tumor bed after surgical removal) in
order to sustain a local secretion of cytokines in the
tumor microenvironment. This has the advantage of
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more closely mimicking the natural biology of cytokine
action (paracrine effect) than does the intravenous ad-
ministration of recombinant cytokines. Cell lines pro-
ducing a viral vector containing the gene of interest can
also be placed intratumorally, leading to the in vivo
transfection of tumor cells. However, locoregional gene
therapy for glioma has major limitations. Firstly, genetic
material is injected in a site where glioma-associated
immunosuppression is probably the strongest, and sec-
ondly, only a small percentage of cells are actually trans-
fected in vivo with current gene delivery techniques. This
latter problem is a major impediment for a tumor that
has infiltrated normal brain structures at an early stage
of development. Despite these theoretical disadvantages,
these approaches are being experimentally investigated
in glioma, particularly with interleukin-4 (IL-4), and
interesting results have been observed in nude mice [95]
and in immunocompetent animals [96].
New approaches to induce apoptosis and death of
glioma cells
Other strategies designed to specifically kill tumor cells
are currently being investigated. Exciting results were
obtained in a rat glioma model using 'suicide genes' [97].
This approach is the prototype of prodrug activation
systems, and consists in transferring into tumor cells a
drug-susceptibility gene which encodes an enzyme that
can activate a prodrug intratumorally. Transduced tu-
mor cells are thus rendered sensitive to drugs that are
otherwise non-cytotoxic. In the particular case of the
'suicide gene', the gene coding for the thymidine kinase
enzyme of the herpes simplex virus (HSV-tk) is trans-
ferred into tumor cells using a viral vector. This gene
is not present in normal cells which are insensitive to
gancyclovir. In contrast, like HSV-infected cells, tumor
cells transduced by HSV-tk gene are killed by gancyclo-
vir since the tk enzyme is able to phosphorylate the anti-
viral drug. In the 9L glioma rat model, major tumor
regressions were obtained, although only a small frac-
tion of tumor cells were shown to be transfected in vivo
by retroviral HSV-tk [97]. The mechanisms responsible
for this so-called 'bystander effect' are not fully under-
stood, even though the passage of phosphorylated
gancyclovir through gap junctions is thought to play an
important role. This 'suicide' strategy is being intensively
investigated in humans, but it is too early to estimate its
significance with the current procedures. Some necroses
around stereotactical injection sites are observed, but
the rate of cell transfection in vivo and the bystander
effect are more limited in humans than in rats. Other
prodrug activation systems are of interest in CNS tu-
mors. Tumor cells may be transfected with a cDNA
encoding the cytochrome P450 2B1, the liver enzyme
catalyzing cyclophosphamide and ifosfamide activation.
When stably transfected with the P450 2B1 gene, the C6
and 9L rat glioma cells are highly sensitive to cyclo-
phosphamide in in vitro and in vivo experiments [98].
Another new and exciting way to treat malig ,ant
glioma emerged from the discovery that these tumors
often express functional Fas (CD95) [99]. Fas is a trans-
membrane glycoprotein belonging to the nerve growth
factor/TNF receptor superfamily: when activated, it
can, like TNF-receptor 1, transduce an apoptotic signal
through its cytoplasmic domain. Apoptosis is triggered
by the binding of Fas to its natural ligand (FasL) or by
cross-linking with anti-Fas antibodies. A high proportion
of human glioma cell lines are sensitive to apoptosis
mediated by anti-Fas antibody in vitro. Others are resist-
ant, but may be rendered sensitive after stable trans-
fection of a human Fas cDNA (100). These results offer
new possibilities for treating glioma with anti-Fas anti-
bodies or soluble FasL. One possible drawback to such
an approach is that other Fas-positive cells may be
affected. Thus, infiltrating leukocyte activity may be re-
duced, restricting strategies relying upon simultaneous
immunoenhancement [84].
Finally, the use of virus as killers was recently sug-
gested to be an additional way to destroy cancer cells.
Adenovirus lacking the E1B protein do not replicate in
normal cells but only in /?55-deficient cells. Such a
'defective' virus can thus destroy tumor cells and spread
to other tumor cells devoid of functional p53. Dramatic
effects have been obtained in vitro and in models using
human xenografts implanted in immunocompromised
mice [101, 102]. No data are available in immunocompe-
tent animals. Thus, a possible limitation of this approach
could be an anti-adenovirus immune response, preclud-
ing repeated administrations of these killers. In addi-
tion, the absence of toxicity of this human adenovirus on
normal cells was demonstrated in rodents, but remains
to be established in man.
Concluding remarks
The place of chemotherapy in the management of ma-
lignant glioma patients is limited. However, it is critical
that the different types of gliomas should not be consid-
ered as a unique entity, and that chemotherapy should be
precisely tailored to the histological diagnosis. The dis-
covery that oligodendroglioma are chemosensitive tumors
is one of the most important advances in these last years
[39]. PCV is clearly indicated at relapse and its place as
an adjuvant therapy will be defined in the near future. In
marked contrast, glioblastoma patients do not benefit
from chemotherapy. Their survival is not improved, and
their quality of life has rarely been evaluated. Develop-
ment of new drugs with strict methodology is required,
but with little validity if not accompanied by a rigorous
assessment of quality of life and cost effectiveness.
Anaplastic astrocytomas are more chemosensitive than
glioblastomas, and there is sometimes obvious reversal
of neurological defects with palliative chemotherapy.
In addition, adjuvant PCV provided young anaplastic
astrocytoma patients with some benefit in survival and
time to progression [35].
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The limited efficacy of chemotherapy (with the excep-
tion of oligodendroglioma) and the absence of survival
improvement for CNS tumors during recent decades
[103] indicate that innovative strategies to treat glioma
patients must be intensively explored. In our opinion, it
is time to propose such experimental strategies instead
of chemotherapy to glioblastoma patients. Anaplastic
astrocytoma patients could also be considered after fail-
ure of a first-line chemotherapy. The dramatic advances
achieved in molecular biology, vector technology and the
current understanding of tumor pathogenesis provide
novel opportunities to attack cancer in a variety of differ-
ent ways. It is clear that future biological therapies will
face great difficulty, since malignant gliomas are diseases
with multiple genetic events, high heterogeneity and con-
stant modifications. However, clinical observation and
biological data suggest that the tumor growth results
from an imbalance between factors promoting cell pro-
liferation versus cell death, angiogenesis stimulators
versus inhibitors and immune evasion versus immune
response. Therefore, there is hope that the correction of
one key biological factor could tilt the balance towards
tumor regression. Indeed, the repair of a single biolog-
ical defect can sometimes induce unexpected effects.
Wild-type p53 may modify the expression of some an-
giogenic and anti-angiogenic factors [104], inhibition of
VEGF could contribute to the maturation of dendritic
cells [105], and interleukin-12 exhibits antiangiogenic
activities [106]. Nevertheless, the current experience in
cancer treatment suggests that several components con-
tributing to carcinogenesis should be targeted to provide
maximal chances of tumor control. Therefore, therapies
based on immuno-enhancement should be joined with
other approaches such as those designed to inhibit neo-
angiogenesis, to restore the control of cell cycle, or to
induce apoptosis. Such an integrated treatment strategy
combining non-antagonistic low toxicity procedures that
attack different components of tumor growth present an
opportunity to improve the disastrous prognosis of pa-
tients suffering from malignant glioma.
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